EP0952834A2 - Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferase - Google Patents
Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferaseInfo
- Publication number
- EP0952834A2 EP0952834A2 EP97921954A EP97921954A EP0952834A2 EP 0952834 A2 EP0952834 A2 EP 0952834A2 EP 97921954 A EP97921954 A EP 97921954A EP 97921954 A EP97921954 A EP 97921954A EP 0952834 A2 EP0952834 A2 EP 0952834A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- ipi
- prenyl transferase
- inhibitor
- bisphosphonate
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 title claims abstract description 106
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 title claims abstract description 106
- 108010065958 Isopentenyl-diphosphate Delta-isomerase Proteins 0.000 title abstract description 5
- 239000003558 transferase inhibitor Substances 0.000 title description 32
- 239000003112 inhibitor Substances 0.000 claims abstract description 79
- 239000003814 drug Substances 0.000 claims abstract description 73
- 229940079593 drug Drugs 0.000 claims abstract description 59
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 24
- 238000011321 prophylaxis Methods 0.000 claims abstract description 16
- 230000000055 hyoplipidemic effect Effects 0.000 claims abstract description 11
- 230000004097 bone metabolism Effects 0.000 claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 8
- 229940122361 Bisphosphonate Drugs 0.000 claims description 118
- 150000004663 bisphosphonates Chemical group 0.000 claims description 115
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 230000006907 apoptotic process Effects 0.000 claims description 33
- 102000016914 ras Proteins Human genes 0.000 claims description 30
- 108010014186 ras Proteins Proteins 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 210000000988 bone and bone Anatomy 0.000 claims description 26
- 230000013823 prenylation Effects 0.000 claims description 26
- 235000012000 cholesterol Nutrition 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 22
- 229940062527 alendronate Drugs 0.000 claims description 22
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 18
- 208000001132 Osteoporosis Diseases 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 17
- 235000011180 diphosphates Nutrition 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 150000003505 terpenes Chemical class 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 230000000123 anti-resoprtive effect Effects 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 229940015872 ibandronate Drugs 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 229930182558 Sterol Natural products 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 8
- 150000003432 sterols Chemical class 0.000 claims description 8
- 235000003702 sterols Nutrition 0.000 claims description 8
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 7
- 206010027452 Metastases to bone Diseases 0.000 claims description 7
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 7
- 208000027868 Paget disease Diseases 0.000 claims description 7
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 7
- 230000000148 hypercalcaemia Effects 0.000 claims description 7
- 208000027202 mammary Paget disease Diseases 0.000 claims description 7
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
- 150000007942 carboxylates Chemical class 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 102000000853 LDL receptors Human genes 0.000 claims description 5
- 108010001831 LDL receptors Proteins 0.000 claims description 5
- LQHYUUBBIJGBNR-UHFFFAOYSA-N OP(O)(=O)S(O)(=O)=O Chemical compound OP(O)(=O)S(O)(=O)=O LQHYUUBBIJGBNR-UHFFFAOYSA-N 0.000 claims description 5
- 229940121659 Prenyltransferase inhibitor Drugs 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 230000002456 anti-arthritic effect Effects 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 230000004715 cellular signal transduction Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000006126 farnesylation Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- 239000000417 fungicide Substances 0.000 claims description 4
- 239000004009 herbicide Substances 0.000 claims description 4
- 230000037356 lipid metabolism Effects 0.000 claims description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 4
- 238000002424 x-ray crystallography Methods 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000004700 cellular uptake Effects 0.000 claims description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
- 229940046231 pamidronate Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 238000008214 LDL Cholesterol Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 238000000099 in vitro assay Methods 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000005976 liver dysfunction Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-L diphosphate(2-) Chemical compound OP([O-])(=O)OP(O)([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-L 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000855 fungicidal effect Effects 0.000 claims 2
- 230000002363 herbicidal effect Effects 0.000 claims 2
- QGKJQRINUQGSJM-UHFFFAOYSA-N 2-dimethylamino-ethyl-diphosphate Chemical group CN(C)CCO[P@](O)(=O)OP(O)(O)=O QGKJQRINUQGSJM-UHFFFAOYSA-N 0.000 claims 1
- 206010020740 Hyperproteinaemia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- JWEQRJSCTFBRSI-PCLIKHOPSA-N rboxylate Chemical compound COC(=O)C1C(N2C3=O)C4=CC=CC=C4OC1(C)N=C2S\C3=C\C(C=1)=CC=C(OC)C=1COC1=CC=CC=C1C JWEQRJSCTFBRSI-PCLIKHOPSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 abstract description 7
- 101710125754 Farnesyl pyrophosphate synthase Proteins 0.000 abstract description 5
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 238000002955 isolation Methods 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003394 isomerase inhibitor Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 32
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 24
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 23
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 23
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 23
- 229950009116 mevastatin Drugs 0.000 description 22
- 210000002997 osteoclast Anatomy 0.000 description 21
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 18
- 230000037361 pathway Effects 0.000 description 17
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 16
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 16
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 16
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 14
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 14
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 13
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 13
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 10
- 108010007622 LDL Lipoproteins Proteins 0.000 description 10
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 9
- 150000002596 lactones Chemical group 0.000 description 9
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 8
- 108700039779 Rab6 Proteins 0.000 description 8
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 229940089617 risedronate Drugs 0.000 description 8
- 108010004103 Chylomicrons Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101150117360 RAB6A gene Proteins 0.000 description 7
- 102100025219 Ras-related protein Rab-6A Human genes 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000020084 Bone disease Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 6
- 229950006971 incadronic acid Drugs 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000004059 squalene synthase inhibitor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 229920002367 Polyisobutene Polymers 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- -1 fatty acid esters Chemical class 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010014476 Elevated cholesterol Diseases 0.000 description 4
- 206010014486 Elevated triglycerides Diseases 0.000 description 4
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 108010047294 Lamins Proteins 0.000 description 4
- 102000006835 Lamins Human genes 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 4
- 229960002286 clodronic acid Drugs 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000006130 geranylgeranylation Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 108091005629 prenylated proteins Proteins 0.000 description 4
- 101710165761 (2E,6E)-farnesyl diphosphate synthase Proteins 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 101710156207 Farnesyl diphosphate synthase Proteins 0.000 description 3
- 101710089428 Farnesyl pyrophosphate synthase erg20 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101710150389 Probable farnesyl diphosphate synthase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 3
- 102100037997 Squalene synthase Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 125000000746 allylic group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002617 bone density conservation agent Substances 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 230000008416 bone turnover Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000005053 lamin Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 2
- 101150102415 Apob gene Proteins 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 2
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 description 2
- 206010059183 Familial hypertriglyceridaemia Diseases 0.000 description 2
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 108010066605 Geranylgeranyl-Diphosphate Geranylgeranyltransferase Proteins 0.000 description 2
- 108010026318 Geranyltranstransferase Proteins 0.000 description 2
- 206010020606 Hyperchylomicronaemia Diseases 0.000 description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 2
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002031 dolichols Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 230000013227 macrophage apoptotic process Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229940057061 mevalonolactone Drugs 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003495 technetium Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ACBOJOPFHNLMLX-UHFFFAOYSA-N (2-hydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl)phosphonic acid Chemical compound CC(C)=CCCC(C)=CCCC(C)=C(O)CP(O)(O)=O ACBOJOPFHNLMLX-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- GGTVPUWEBRGMCO-UHFFFAOYSA-N 6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[5-hydroxy-6-methyl-4-(pyridin-3-ylmethylamino)oxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(=O)CO)CC1OC(OC(C)C1O)CC1NCC1=CC=CN=C1 GGTVPUWEBRGMCO-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100022299 All trans-polyprenyl-diphosphate synthase PDSS1 Human genes 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000224495 Dictyostelium Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 102100027665 Isopentenyl-diphosphate Delta-isomerase 1 Human genes 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 108010021101 Lamin Type B Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101001135788 Pinus taeda (+)-alpha-pinene synthase, chloroplastic Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229910004856 P—O—P Inorganic materials 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101710158136 Trans-prenyltransferase Proteins 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- JXBAVRIYDKLCOE-UHFFFAOYSA-N [C].[P] Chemical compound [C].[P] JXBAVRIYDKLCOE-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 108010069282 cis-prenyl transferase Proteins 0.000 description 1
- 229960002577 colestipol hydrochloride Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 108091005640 farnesylated proteins Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 1
- 108091005639 geranylgeranylated proteins Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 230000012105 intracellular pH reduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000009063 long-term regulation Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 230000011234 negative regulation of signal transduction Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000002353 nuclear lamina Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000006506 pH homeostasis Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010075398 prelamin A Proteins 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000013498 protein farnesylation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 102000016731 rac GTP-Binding Proteins Human genes 0.000 description 1
- 108010092883 rac GTP-Binding Proteins Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000006456 reductive dimerization reaction Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
Definitions
- the present invention relates to prenyl transferase (farnesyl pyrophosphate synthase) and isopentenyl pyrophosphate isomerase (IPI) inhibitors, and to the use of such inhibitors in various forms of therapy and prophylaxis.
- the present invention relates to the field of bone metabolism (e.g. bone resorption), and in particular to the use of prenyl transferase and IPI inhibitors in the treatment of various diseases and disorders of bone metabolism and to the use of prenyl transferase in the screening, isolation, synthesis and evaluation of osteoactive drugs.
- Lipids occur in the blood mainly as cholesterol and triglycerides, with smaller amounts of phospholipids, fatty acids, and fatty acid esters.
- cholesterol and triglycerides are complexed with proteins (known as apolipoproteins) and transported in the form of lipoprotein particles.
- the lipoprotein particle surface is composed largely of phospholipid, free cholesterol and protein, and the core contains mostly triglyceride and cholesterol esters.
- Lipoprotein particles are divided into four major groups on the basis of density, composition and electrophoretic mobility. Chylomicrons are formed in the intestine and are large triglyceride-rich particles derived from dietary fat. Very low density lipoproteins (hereinafter VLDLs) are composed largely of endogenous triglycerides and are synthesised in the liver. Low density lipoproteins (hereinafter LDLs) are rich in cholesterol and are mainly end products of VLDL catabolism. High density lipoproteins (HDLs) contain about 50% protein, are produced in the liver and intestine and act as acceptors of lipids, especially free cholesterol.
- VLDLs Very low density lipoproteins
- LDLs Low density lipoproteins
- HDLs High density lipoproteins
- Hyperlipidaemia (or hyperlipoproteinaemia) embraces a group of disorders associated with elevated levels of lipids in the blood. Hyperlipidaemias may be inherited or secondary to dietary factors, excessive alcohol intake or primary disease states (such as hypothyroidism and diabetes mellitus) , and can also arise as a side effect of various drug treatments (e.g. the administration of beta-blockers, corticosteroids, oestrogens, oral contraceptives or thiazide diuretics). Other factors affecting the lipid composition of the blood include physical activity, age and sex.
- Type I hyperchylomicronaemia characterised by the presence of chylomicrons and by normal or only slightly increased concentrations of very low- density lipoproteins;
- Type Ila hyper- ⁇ -lipoproteinaemia characterised by an elevation in the concentration of low-density lipoproteins
- Type lib characterised by an elevation in the concentration of low-density lipoproteins and of very low-density lipoproteins
- Type III (floating ⁇ " or “broad fl” pattern) characterised by the presence of very low-density lipoproteins having an abnormally high cholesterol content and an abnormal electrophoretic mobility;
- Type IV hyperpre- ⁇ -lipoproteinaemia characterised by an elevation in the concentration of very low- density lipoproteins , but no increase in the concentration of low-density lipoproteins, and by the absence of chylomicrons ;
- Typ e v hyperpre- ⁇ -lipoproteinaemia and chylomicronaemia characterised by an elevation in the concentration of very low-density lipoproteins and the presence of chylomicrons.
- Primary hyperlipidaemias may also be classified according to the genetic and metabolic disorder resulting in the following categories:
- familial hypercholesterolaemia which is usually heterozygous but very rarely may be homozygous, characterised by a type Ila pattern (occasionally a type lib pattern is present) ;
- familial combined hyper lipidaemia characterised by elevated cholesterol only, elevated triglyceride only, or elevated cholesterol and triglyceride - type Ila, type IV, or type lib patterns may be found;
- familial dysbetalipoproteinaemia familial dysbetalipoproteinaemia (remnant hyperlipoproteinaemia or broad- ⁇ disease) showing the type III pattern;
- hypolipidaemic agents can find application in the treatment and prophylaxis of a wide range of cardiovascular disorders associated with hyperlipidaemia.
- bile acid sequestrants colestipol hydrochloride and cholestyramine
- niacin probucol
- gemfibrozil neomycin sulphate
- statins are the "statins" (Hoeg and Brewer, 1987, JAMA, Vol.258 (24), pages 3532-3536). These compounds act at the beginning cf the cholesterol biosynthetic pathway (see Figure 1) by competitively inhibiting 3 -hydroxy- 3 -methylglut aryl coenzyme A reductase (herinafter HMGCoAR, the rate determining enzyme for cholesterol synthesis). All of the statins presently in use are HMG-CoA analogues, and include mevastatin (compactin), lovastatin (mevinolin), prevastatin (eptastatin) and simvastatin (synvinolin) .
- statins work by increasing the cataboiism of LDL as well as decreasing its synthesis.
- LDL particles contain apolipoprotein B (apoB) , and are removed from circulation by means of high affinity LDL receptors which recognize apoB. These receptors are upregulated by the cholesterol depletion induced by the statins.
- apoB apolipoprotein B
- LDL receptors which recognize apoB.
- HMGCoAR inhibitors as hypolipidaemic agents is associated with several problems.
- Adverse reactions include gastro-intestinal disturbances, headache, rash and pruritus. Liver damage can occur in hepatocompromized subjects, as well as myositis with increased values for creatine phosphokinase.
- severe muscle effects including myolysis, rhabdomyoiysis, myositis and myolitis
- the inhibitors may also interfere with DNA replication and there are reports of carcinogenicity and teratogenicity.
- Nonresponders can amount to 20% of the target patient population, not including those patients lacking functional LDL receptors (such as those homozygous for familial hypercholesterolaemia) which also fail to respond.
- statins Some workers have ascribed certain side effects to the fact that the metabolic block induced by the statins effectively shuts down the isoprenoid biosynthetic pathways which lead from farnesyl pyrophosphate to a large number of different products (including ubiquinone and dolichol) . Since many of these products are essential for cell viability, it has been suggested that at least some of the side effects associated with the statins might arise from the block imposed on the isoprenoid pathways rather than from that on cholesterol biosynthesis per se.
- statins particularly those associated with the alleviation of cardiovascular disease events associated with hyperlipidaemia
- mevalonate pathway products other than cholesterol particularly the isoprenoids
- eff ective inhibition of the cholesterol biosynthetic pathway depends to a significant extent on negative feedback arising from suppression of other isoprenoid pathways .
- the squalene synthase inhibitors may not be as effective as the statins in alleviating cardiovascular disease attendant on hyper lipidaemia , and may be less effective in lowering cholesterol levels .
- hypolipidaemics which exhibit reduced side effects and increased efficacy and breadth of application .
- Bone destruction can result from various cancers and also from rheumatoid arthritis .
- Metabolic bone disorders commonly involve excessive bone resorption and include
- Paget ' ⁇ disease hypercalcaemia (both tumour-induced and non-tumour induced), bone metastases and osteoporosis.
- Paget's disease (a focal increase in bone turnover) is fairly common, and in some countries affects up to 5% of the population over 50 years of age.
- the disease may be caused by a slow virus infection, and leads to bone pain, deformities and fractures.
- Bone metastases can induce bone destruction either through local invasion or via the secretion of bone- resorbing agents into the blood stream.
- Hypercalcaemia can result either from an increase in the flow of calcium from bone or the intestine to the blood, or from an increase in tubular reabsorption of calcium in the kidney. It can induce a wide variety of physiological disturbances and can be life threatening.
- Osteoporosis is characterized by a reduction in the quantity of bone leading to atrophy of skeletal tissue.
- osteoporosis is another common symptom.
- Primary osteoporosis is the result of an identifiable disease process or agent, while primary osteoporosis (which constitutes about 90% of all cases) includes postmenopausal osteoporosis, age-associated osteoporosis (affecting a majority of individuals over the age of 70) and idiopathic osteoporosis affecting middle-aged and younger men and women.
- Bone remodeling occurs throughout life, renewing the skeleton and maintaining the strength of bone.
- This remodelling involves the erosion and filling of discrete sites on the surface of bones by an organized group of cells called “basic multicellular units” or "BMUs".
- BMUs basic multicellular units
- 3MUs primarily consist of osteoclasts, osteoblasts, and their cellular precursors.
- bone is resorbed at the site of an "activated" BMU by an osteoclast, forming a resorption cavity. This cavity is then filled with bone by osteoblasts.
- compositions and methods are described in the medical literature for the treatment of the above- described diseases and conditions, and most attempt to either slow the loss of bone or produce a net gain in bone mass.
- oestrogen has been used as a means both to prevent and to treat osteoporosis in postmenopausal women.
- the use of oestrogen has been associated with certain side effects, such as uterine bleeding.
- Other treatments are based on the administration of parathyroid hormone.
- the hormone calcitonin has also been used to treat Paget's disease (and to a lesser extent tumour bone disease) , and can be effective in decreasing bone turnover.
- Paget's disease and to a lesser extent tumour bone disease
- the incidence of relapse is high, and side effects on the vascular system limit the therapeutic usefulness of calcitonin.
- One of the most successful class of drugs f or the treatment of the above diseases has proved to be the bisphosphonates .
- inorganic pyrophosphate and polyphosphate have high affinity for bone mineral and are able to inhibit the precipitation and dissolution of calcium phosphate crystals in vitro and to inhibit bone mineralization in vivo .
- These activities are thought to arise from direct physicochemical effects (such as adsorption to hydroxyapatite , inhibition of dissolution of hydroxyapatite and crystal growth inhibition) .
- Pyrophosphates have therefore found application as bone imaging agents for diagnostic purposes ( usually in the form of ' ' " technetium derivatives ) and as antitartar agents for use in toothpastes .
- inorganic pyrophosphates are rapidly hydrolysed following administration (particularly oral administration) due to the presence of the relatively labile phosphorus-oxygen bond P-O-P .
- This severely limits their pharmaceutical utility and has prompted a search for PPi analogues which exhibit similar physicochemical activities while resisting enzymatic hydrolysis in vivo .
- Bisphosphonates which are characterized by phosphorus- carbon (P-C-P) bonds, are stable analogues of naturally occurring inorganic pyrophosphates which to a great extent overcome the limitations associated with inorganic pyrophosphates. Bisphosphonates are resistant to chemical and enzymatic hydrolysis but retain the therapeutic activity of PPi.
- bisphosphonates exhibit properties which extend beyond those attributable to purely physicochemical phenomena.
- bisphosphonates have been found to be inhibitors of osteoclast-mediated bone resorption in organ cultures of bone and in animal models.
- Bisphosphonates therefore have broader clinical utility than PPi, and have found widespread application in four main clinical areas: (a) as bone imaging agents for diagnostic purposes, usually in the form of ' ' " technetium derivatives, (b) as anti- resorptive agents to combat bone loss associated with Paget 's disease, hypercalcaemia associated with malignancy and bone metastases or osteoporosis, (c) as calcification inhibitors in patients with ectopic calcification and ossification, and (d) as a ⁇ titartar agents for use in toothpastes.
- Bisphosphonates are now among the most important therapeutic agents for the treatment of pathological disorders of bone metabolism, including osteoporosis . Moreover, since some bisphosphonates appear to have anti- inflammatory as well as anti-resorptive effects in vivo , they may also have utility in the treatment of inflammation and rheumatoid arthritis .
- bisphosphonates may affect the differentiation and recruitment of osteoclast precursors or alter the capacity of mature osteoclasts to resorb bone by altering the permeability of the osteoclast membrane to small ions .
- Another hypothesis is that they act by affecting lysosomal enzyme production or cell metabolism or through toxic effects on osteoclasts .
- a further suggestion is that bisphosphonates affect other cells in the bone microenvironment that regulate the activity of the osteoclasts that are involved in the antiresorptive mechanism.
- the bisphosphonates represent a important class of drug which has opened up new approaches in the therapy of bone diseases .
- the bisphosphonates are characterized by poor intestinal absorption and the ideal bisphosphonate would show substantial and consistent intestinal absorption, consistent and reversible effects on bone turnover, low toxicity and (for appropriate treatment regimens) shortened residence time in bone.
- Present bisphosphonates fulfil these ideals only to a limited degree.
- prenyl transferase catalyzes the condensation of isopentenyl pyrophosphate with an allylic pyrophosphate at a point in the sterol biosynthetic pathway just prior to the branchpoint into the sterol and isoprenoid pathways (see Figures 1 and 3).
- Isopentenyl pyrophosphate isomerase catalyses interconversion of isopentenyl pyrophosphate and dimethylallyl pyrophosphate ( Figure 3 ⁇ via a carbocation intermediate.
- IPI and/or prenyl transferase inhibitors for use in various forms of therapy and prophylaxis.
- the IPI and/or prenyl transferase inhibitors of the present invention find particular utility in the modulation of lipid metabolism, cell proliferation, isoprenoid-related cellular apoptosis and cellular signal transduction.
- the IPI and/or prenyl transferase inhibitors are also useful as fungicides or herbicides.
- the inhibitors may have dual inhibitory activity, and inhibit both IPI and prenyl transferase. They may also inhibit other isoprenoid synthetic enzymes.
- the present invention also provides a new class of antiresorptive (osteoactive) drugs based on the presence of IPI and/or prenyl transferase inhibitory activity, and provides methods for rapidly and efficiently screening a large number of potential osteoactive drugs (e.g. improved osteoactive bisphosphonates) and for the identification and synthesis of compounds having improved antiresorptive and/or anti-inflammatory activity.
- osteoactive drugs e.g. improved osteoactive bisphosphonates
- Prenyl transferase inhibitors, IPI inhibitors and inhibitors of IPI and/or prenyl transferase lipid metabolism, cell proliferation, apoptosis and signal transduction
- Prenyl transferase catalyzes the condensation of isopentenyl pyrophosphate with an allylic pyrophosphate
- the prenyl transferase inhibitors of the present invention are inhibitors of this enzyme. It is specific for isopentenyl pyrophosphate but can use either the 5-carbon dimethylallyl pyrophosphate (farnesyl diphosphate synthase I) or the 10 carbon geranyl pyrophosphate
- the site of action of the IPI and prenyl transferase inhibitors of the present invention is shown in Figure 1 , along with those of the known HMGCoA reductase and squalene synthase inhibitors. It can be seen that the IPI and/or prenyl transferase inhibitors of the present invention act at a point in the cholesterol biosynthetic pathway before the synthesis of farnesyl pyrophosphate. In contrast, the known squalene synthase inhibitors act after the synthesis of farnesyl pyrophosphate.
- the IPI and/or prenyl transferase inhibitors of the invention are upstream inhibitors, in that they inhibit both the cholesterol biosynthetic pathway and the various isoprenoid pathways.
- the IPI and/or prenyl transferase inhibitors of the invention act at the step immediately preceding the branch point into the various cholesterol/isoprenoid pathways. This has important consequences with respect to the nature of the perturbations induced in the pools of mevaionate metabolites, as explained below.
- HMGCoA reductase mediates the rate-determining step of cholesterol biosynthesis and is the most elaborately regulated enzyme of the cholesterol biosynthetic pathway. It is subject to control by both competitive and allosteric mechanisms, by phosphorylation and dephosphorylation as well as by long-term regulation. Cholesterol and other metabolites are feedback regulators of the enzyme.
- inhibition of HMGCoA reductase profoundly perturbs the sizes of a large number of different metabolite pools, and some of the side effects associated with the use of the statins arise from these perturbations.
- the reduction of cholesterol levels relieves negative feedback on the HMGCoA reductase and results in a large increase in the effective concentration of the enzyme. This blunts the effect of the statins and limits the extent of cholesterol reductions attainable.
- the IPI and/or prenyl transferase inhibitors of the present invention do not act directly on HMGCoA reductase and so disrupt a smaller range of metabolite pools than the statins. They therefore have important benefits as hypolipidaemics. in particular, they exhibit reduced side effects, greater activity as hypolipidaemics and can be used in a broader class of patients.
- the IPI and/or prenyl transferase inhibitors of the invention can be used as hypolipidaemic agents, and in particular as hypocholesterolaemic agents. They find application in lowering serum cholesterol levels, in the treatment or prophylaxis of hypercholesterolaemia, hyperlipidaemia, hyperlipoproteinaemia, nephrotic hyperlipidaemia or atherosclerosis, in increasing HDL cholesterol levels while lowering LDL cholesterol and serum triglyceride levels, in the treatment or prophylaxis of cardiovascular disease (e.g. atherosclerosis and other arterial lesions) and for the prevention of restenosis after coronary angioplasty.
- cardiovascular disease e.g. atherosclerosis and other arterial lesions
- IP! and/or prenyl transferase inhibitors of the invention may be administered to any or all of the following classes of patients: (a) hepatocompromized individuals; (b) individuals with a prior history of liver dysfunction;
- mammals e.g. humans
- IPI and/or prenyl transferase inhibitors of the invention may be used in the treatments of any cf the following types of hyperlipoproteinaemias:
- Type I hyperchylomicronaemia characterised by the presence of chylomicrons and by normal or only slightly increased concentrations of very low- density lipoproteins;
- Type Ila hyper- ⁇ -lipoproteinaemia characterised by an elevation in the concentration of low-density lipoproteins
- Type lib characterised by an elevation in the concentration of low-density lipoproteins and of very low-density lipoproteins
- Type III ('floating ⁇ ' or 'broad ⁇ pattern) characterised by the presence of very low-density lipoproteins having an abnormally high cholesterol content and an abnormal electrophoretic mobility;
- Type IV hyperpre- ⁇ -lipoproteinaemial characterised by an elevation in the concentration of very low- density lipoproteins, but no increase in the concentration of low-density lipoproteins, and by the absence of chylomicrons
- Type V 'hyperpre- ⁇ -lipoproteinaemia and chylomicronaemia' characterised by an elevation in the concentration of very low-density lipoproteins and the presence of chylomicrons.
- familial hypercholesterolaemia which is usually heterozygous but very rarely may be homozygous, characterised by a type Ila pattern (occasionally a type lib pattern is present) ;
- familial dysbetalipoproteinaemia familial dysbetalipoproteinaemia (remnant hyperiipoproteinaemia or broad- ⁇ disease) showing the type III pattern; and (e) lipoprotein lipase deficiency or apolipoprotein C-ll deficiency showing a type I of type V pattern.
- the IPI and/or prenyl transferase inhibitors of the invention also find application in the modulation of cell proliferation and in particular in the treatment of prophylaxis of disorders involving cell proliferation (for example various cancers, including cancers and cancer metastases in bone) .
- IPI and/or prenyl transferase inhibitors block the synthesis of these products, and are therefore also useful in the treatment of diseases characterised by cell proliferation.
- the prenyl transferase and/or IPI inhibitors of the invention also potentiate the effects of other drugs and treatments affecting cellular growth, such as radiotherapy, surgery and drugs used in cancer chemotherapy, immunotherapy or immunosuppression.
- the IPI and/or prenyl transferase inhibitors of the present invention may be administered as adjuncts to radiotherapy, chemotherapy, immunotherapy or surgery in the treatment of cancer, particularly of ras-related cancers.
- ras- related cancers include lung, bladder, colon and brain cancers.
- Protein-prenyl transferase acts at a point downstream of farnesyl pyrophosphate (see Figure 1 ) and the inhibitors described in EP0537008 do not block or reduce the flow of farnesyl pyrophosphate into the various prenylation pathways. In this respect they differ fundamentally from the IPI and/or prenyl transferase inhibitors of the present invention.
- the anti-cancer activity of the IPI and/or prenyl transferase inhibitors of the invention arise from a block of protein prenylation (for example, prenylation of CaaX box containing proteins such as the G proteins, members of the ras family and other oncoproteins) by reducing or eliminating input into the isoprenoid pathways shown in Figure 1 .
- protein prenylation for example, prenylation of CaaX box containing proteins such as the G proteins, members of the ras family and other oncoproteins
- doiichol pools blocks the synthesis of glycoproteins and changes membrane fluidity, which are important for cell growth.
- the IPI and/or prenyl transferase inhibitors of the present invention reduce metabolic pools of prenyls (e.g. farnesyl pyrophosphate) which are involved in the post-translational modification of CaaX box containing proteins (including proteins in the r_as family and G-proteins).
- prenyls e.g. farnesyl pyrophosphate
- the inhibitors of the present invention reduce metabolic pools of farnesyl pyrophosphate, which is the donor of the farnesyl group to CaaX box containing proteins such as the ras p21 oncoprotein.
- the activity of CaaX containing proteins such as the ras oncoprotein and G proteins can be blocked by preventing their post-translational modification by administration of the inhibitors of the invention.
- the prenyl transferase and/or IPI inhibitors of the invention can be used to prevent prenylation
- the inhibitors of the present invention find application in the treatment and/or prophylaxis of tumours.
- the prenyl transferase and/or IPI inhibitors of the invention are used to prevent or reduce the farnesylation of ras in the modulation of cell proliferation, isoprenoid-related cellular apoptosis or cellular signal transduction.
- the inhibitors of the present invention also find application in the modulation of isoprenoid-related cellular apoptosis, for example in the treatment or proyphlaxis of various autoimmune diseases (such as rheumatoid arthritis) and chronic inflammatory diseases.
- the inhibitors of the present invention also find application in the modulation of cellular signal transduction, for example in the treatment or prophylaxis of graft (e.g. allograft) rejection.
- Protein prenylation increases protein hydrophobicity and promotes protein- membrane interactions.
- Prenytated ras protein localizes to the inner cell membrane and appears to function as a mediator through which various peptide growth factors and cytokines signal to stimulate intracellular events.
- Binding of these substances to their respective receptors on target cells activates ras and triggers inter alia cell proliferation, differentiation, and T-cell activation.
- the inhibitors of the invention block or reduce ras prenylation, and ras has now been discovered to play an important role in chronic allograft rejection (O'Donnell et al. , 1995,
- the prenyl transferase inhibitors of the invention ameliorate chronic rejection.
- the IPI and/or prenyl transferase inhibitors of the present invention can also be used to block sterol synthesis in plants and fungi . They therefore find utility as fungicides and/or herbicides.
- IPI and/or prenyl transferase inhibitors of the invention are thought to act as stable analogues of the carbocation intermediate shown in Figure 2, thereby blocking the synthesis of farnesyl pyrophosphate.
- prenyl transferase inhibitors of the present invention preferably comprise structural and/or functional analogues of the carbocation:
- analogues may be bisphosphonates (either geminal or non geminal bisphosphonates), and may be structural and/or functional analogues of the carbocation:
- R is an alkyl side chain, for example having > 5 (for example about 10) carbon atoms.
- the analogues may also be sulphonates, carboxylates, phosphonocarboxylates, phosphonosulphonates, phosphonophosphates, or pyrophosphates.
- Preferred inhibitors constitute a subclass of bisphosphonates which inhibit either or both of IPI and prenyl transferase (the latter hereinafter referred to as prenyl transferase inhibitory bisphosphonates or PIBs and the former as IPI inhibitory bisphosphonates or IPIBs), or analogues or derivatives thereof.
- the IPIB/PIB is preferably selected from the large number of known osteoactive bisphosphonates (see e.g. Fleisch, H., 1993, Bisphosphonates in bone disease, ISBN 3-9520459-0-X, the contents of which are incorporated herein by reference).
- the IPI and/or prenyl transferase inhibitor of the invention may also be an analogue or derivative of the osteoactive IPIB or PIB, for example a derivative having a group for promoting cellular uptake (e.g. a lipophilic group or a dipeptide group).
- a derivative having a group for promoting cellular uptake e.g. a lipophilic group or a dipeptide group.
- the IPI and/or prenyl transferase inhibitors have a positively charged nitrogen atom.
- Particularly preferred are PIBs or IPIBs having a positively charged nitrogen atom.
- Examples of such bisphosphonates are alendronate, pamidronate and ibandronate, and analogues or derivatives thereof including nitrogen ring-containing (heterocyclic) compounds.
- the IPI prenyl transferase inhibitors may be modified in a variety of ways to modify their pharmacokinetics and in vivo localization.
- the IPl/prenyl transferase inhibitors may be modified or derivatized to render them more lipophilic using techniques known to those skilled in the art.
- the inhibitors may be modified by the attachment of a lipophilic group or of a dipeptide group permitting uptake via the cellular plasma membrane peptide carrier system (see e.g. work by Breuer et al at the School of Pharmacy at the Hebrew University of Jerusalem).
- inhibitors of the invention may be prodrugs having enhanced bioavailablity.
- the prenyl transferase/IPI inhibitors When used to treat cancers, the prenyl transferase/IPI inhibitors may be modified to target them to the tumour site.
- the IPIBs/PIBs accumulate in bone, and so are particularly preferred in the treatment of cancers and cancer metastases in bone.
- the invention also relates to the use of an IPI and/or prenyl transferase inhibitor for the manufacture of a medicament for the regulation of bone metabolism, for example in the treatment of Paget's disease, hypercalcaemia (both tumour-induced and non- tumour induced), bone metastases or osteoporosis in both men and women (e.g. associated with secondary causes such as administration of glucocorticoids), wherein the inhibitor is not a geminal bisphosphonate.
- the invention permits the identification of improved phosphonate drugs with reduced affinity for bone.
- the invention relates to an IPI and/or prenyl transferase inhibitor for use in therapy or prophylaxis, e.g. in the manufacture of a medicament for the regulation of bone metabolism, for example in the treatment of Paget's disease, hypercalcaemia (both tumour-induced and non-tumour induced), bone metastases or osteoporosis, wherein the inhibitor is not a geminal bisphosphonate.
- bisphosphonate is used herein in a broad sense to cover not only bisphosphonate sensu stricto, but also bisphosphonate analogues.
- Bisphosphonate analogues are those ligands which can compete with osteoactive bisphosphonate for binding to the IPI and/or prenyl transferase of the invention, or which can compete ijn vitro (for example, on an affinity column) with osteoactive bisphosphonate (in either the free state or in the form of a derivative linked to an affinity column) for binding to the IPI and/or prenyl transferase of the invention.
- Bisphosphonate analogues include pyridoxal phosphate, 0- phosphorylethanolami ⁇ e, o-phosphorylcholine, phosphatidyl ethanolamine and phospholipid bisphosphonate analogues.
- Osteoactive drugs are those which act as antiresorptive and/or anti-inflammatory drugs in vivo.
- the prenyl transferase and/or IPI inhibitor for use in the therapies listed above is preferably a structural and/or functional analogue of the carbocation:
- analogues may be bisphosphonates (either geminal or non geminal bisphosphonates), and may be structural and/or functional analogues of the carbocation:
- R is an alkyl side chain, for example having >5 (for example about 10) carbon atoms.
- the inhibitors may also be sulphonates, carboxylates, phosphonocarboxylates, phosphonosulphonates, phosphonophosphates, or pyrophosphates.
- the IPI and/or prenyl transferase inhibitor may comprise a positively charged nitrogen atom.
- the invention also contemplates the use of IPI and/or prenyl transferase for binding a bisphosphonate, for example in an in vitro assay.
- the IPI and/or prenyl transferase is one which, in vivo, mediates the physiological (e.g. antiresorptive) effects of osteoactive bisphosphonate. It may also be a Dictvostelium spp., for example Dictvostelium discoideum, prenyl transferase.
- the invention also embraces a method for screening for osteoactive drugs (e.g. bisphosphonates) comprising the steps of: (a) contacting a putative drug (e.g. a bisphosphonate) with the IPI and/or prenyl transferase of the invention, and (b) determining whether interaction (e.g. binding) between the putative drug and IPI and/or prenyl transferase occurs, wherein interaction is indicative of an osteoactive drug (e.g. an osteoactive bisphosphonate).
- the relative affinity (interaction) with IPI and prenyl transferase may also be determined in the methods of the invention.
- the presence or degree of interaction between the putative drug and IPI and/or prenyl transferase is measured or determined by an enzyme inhibition assay.
- enzyme inhibition assays may be conducted according to any of the standard IPI and/or prenyl transferase assay protocols known to those skilled in the art.
- the method described above is useful for screening large numbers of synthetic drugs for therapeutic activity. It may also be used to classify potential osteoactive or anti-arthritic bisphosphonates into different groups according to their mode of action (or their cellular targets) . Preferably, the method is employed in high throughput screening of drug candidates. Compounds identified by the method of the invention can be further modified or used directly as therapeutic compounds, for example in the treatment of osteoporosis.
- a method for evaluating the therapeutic activity of a putative drug comprising the steps of: (a) contacting the drug with IPI and/or prenyl transferase, and (b) measuring the binding affinity of the putative drug for the prenyl transferase and/or IPI, or the relative binding affinities for prenyl transferase and IPI.
- a putative drug e.g. a bisphosphonate
- the method described above is useful e.g. for ranking the therapeutic activity of potential drugs (e.g. potential bisphosphonate drugs).
- the invention in another aspect relates to a method for synthesising a therapeutically active (e.g. antiresorptive or antiarthritic) drug (e.g. a bisphosphonate) comprising the steps of: (a) providing a three- dimensional model comprising a catalytic site of the prenyl transferase of the invention (e.g. by computer analysis of its amino- acid sequence or by X-ray crystallography of the prenyl transferase or fragment thereof), and (b) modelling the therapeutically active drug with reference to the three-dimensional model generated in step (a).
- a therapeutically active drug e.g. antiresorptive or antiarthritic
- a bisphosphonate e.g. a bisphosphonate
- the three- dimensional model is generated by computer analysis of the amino- acid sequence of all or a portion of the IPI prenyl transferase (for example a catalytic site thereof or a bisphosphonate binding domain thereof). Examples of such models are known to those skilled in the art.
- the three-dimensional model could be generated by X- ray crystallography of prenyl transferase/IPI (or fragments/derivatives thereof), or by NMR techniques. These techniques could also be applied to the IPI/prenyl transferase-drug (e.g. IPI/prenyl transferase-bisphosphonate) complex, the results of which could also be used as the basis for the rational design of therapeutic agents.
- IPI/prenyl transferase-drug e.g. IPI/prenyl transferase-bisphosphonate
- the invention also covers therapeutically active drugs (e.g. a bisphosphonate) which have been screened, evaluated or synthesised by the methods of the invention.
- therapeutically active drugs e.g. a bisphosphonate
- the invention also contemplates an antibody (e.g. a monoclonal antibody) which binds to the IPI and/or prenyl transferase of the invention.
- an antibody e.g. a monoclonal antibody which binds to the IPI and/or prenyl transferase of the invention.
- the antibodies of the invention may advantageously bind specifically to the IPI and/or prenyl transferase of the invention (e.g. specifically to both) .
- Antibodies specific for the catalytic site of IPI and/or prenyl transferase may act as bisphosphonate mimetics.
- osteoactive drug targets e.g. bisphosphonate targets
- degree of occupancy of drug targets in patients undergoing therapy may be exploited in imaging techniques, for example to assess the extent to which osteoactive drug targets (e.g. bisphosphonate targets) are available for drug action, or to determine the degree of occupancy of drug targets in patients undergoing therapy.
- the invention also contemplates antibody derivatives, including antibody fragments (e.g. Fab fragments), chimaeric antibodies
- antibody derivatives including humanized antibodies and antibody derivatives (such as fusion derivatives comprising an antibody-derived variable region and a non-immunoglobulin peptide having for example enzyme or conjugative activity).
- test kits comprising the IPI and/or prenyl transferase of the invention, for example for use in the screening or evaluation methods of the invention.
- the IPI and/or prenyl transferase may be bound to a solid support and/or
- the kit further may comprise a labelled (e.g. radiolabelled or f luorescently labelled) bisphosphonate and/or
- the kit may further comprise the antibody of the invention.
- kits per se.
- the invention contemplates the IPI prenyl transferase of the invention when bound to a solid support.
- Also contemplated by the invention is a mimetic or
- the mimetic for example consisting essentially of the catalytic or bisphosphonate binding site of IPI or prenyl transferase .
- the invention also contemplates various therapeutic applications for the antibody , mimetic or antagonist of the invention .
- the invention relates to a process for producing an osteoactive drug comprising the step of providing an analogue of the carbocation:
- the invention relates to a process for selectively inhibiting an enzyme involved in sterol/isopren ⁇ id biosynthesis comprising the step of providing an analogue of the carbocation :
- analogue has a positively charged nitrcger. atom in an alkvl chain thereof.
- the carbocation preferably is :
- R is an alkyl side chain, for example having >5 ( for example about 10 or about 15 ) carbon atoms .
- analogues are bisphosphonates having a formula selected from:
- the enzyme to be selectively inhibited is preferably selected from the enzymes squalene synthase , protein prenyl transferase, cis-prenyl transferase and trans- prenyl transferase (geranylgeranylpyrophosphate synthase) .
- the selectivity of inhibition need not be absolute, and the compounds of the invention may inhibit two or more of the above-listed enzymes.
- the spectrum of inhibitory activity over the enzymes listed above i.e. the relative or absolute inhibitory specificity
- greater inhibitory selectivity can be achieved by providing a long (e.g. about C; s or longer) carbon side chain.
- the invention therefore also contemplates a method of varying the inhibitory profile of an inhibitor of enzyme(s) involved in sterol/isoprenoid biosynthesis by varying the length of the carbon side chain shown in the general formula below:
- Such inhibitors preferably have the formula:
- Drugs based on or derived from such inhibitors would allow specific inhibition of prenylation of proteins that are modified by a geranylgeranyl group without inhibiting sterol biosynthesis or protein farnesylation .
- the drug or inhibitor may not be a bisphosphonate .
- the drug or inhibitor may be a bisphosphonate (for example a geminal or non geminal bisphosphonate) , sulphonate , carboxylate , phosphonocarb ⁇ xylate , phosphonosulphonate , ph ⁇ sphoncphosphate or pyrophosphate .
- the drug or inhibitor may be further modified to facilitate cellular uptake , for example by the attachment of a liDCDhiiic group or by the attachment of a dipeptide group permitting uptake via the cellular plasma membrane peptide carrier system.
- the invention in another aspect relates to a process for increasing the therapeutic efficacy of an osteoactive -4V- bisphosphonate comprising the step of introducing a positively charged nitrogen atom into an alkyl chain thereof.
- the IPI and/or prenyl transferase inhibitors of the invention can be administered in a variety of forms, including oral and parental routes.
- Parental administration can be intravenous, intramuscular, subcutaneous, intrasynovial, transdermal, intraocular, sublingual, buccal, topically or rectal.
- Other routes include nasal inhalation e.g. via a nebulizer, atomizer or aerosol.
- Tne IPI and/or prenyl transferase inhibitors may be formulated in an inert diluent or with an assimilable edible carrier. It may be enclosed in hard or soft shell capsules or compressed into tablets.
- the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups or wafers.
- Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 10 and about 1000 mg (e.g. between 50 and 300 mg) of active compound.
- the tablets, troches, pills, capsules and the like may also contain a binder (for example corn starch or gelatin) , excipients such as dicalcium phosphate, disintegrating agents, lubricants and sweetening cr flavouring agents.
- a binder for example corn starch or gelatin
- excipients such as dicalcium phosphate, disintegrating agents, lubricants and sweetening cr flavouring agents.
- the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier.
- Unit dosage forms are pharmaceutically pure.
- the inhibitors may be incorporated into sustained-release preparations and formulations.
- the active compound may also be administered carenterally or intraperitoneally.
- Solutions or suspensions of the active compounds or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant.
- Dispersion can also be prepared in glycerol, liquid polyethylene glycols, mixtures thereof and oils.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the dosage of the inhibitors is determined by the physician and varies with the form of administration, the active compound selected and the patient under treatment.
- the therapeutic dosage will generally be from about 0.1 to about 100 mg/kg/dy and may be administered in several different unit dosage form. Higher dosages may be required for oral administration.
- Example 1 Inhibition of farnesyl diphosphate synthase (prenyl transferase) and IPI by bisphosphonates
- Clodronate, alendronate, ibandronate, YM 1 75 and risedronate were provided by Procter and Gamble Pharmaceuticals, Cincinnati, OH.
- the bisphosphonates were dissolved in PBS, the pH adjusted to 7.4 with 1 N NaOH, then filter-sterilised by using a 0.2 ⁇ m filter.
- Mevastatin also known as compactin
- the pH of the solution was adjusted to approximately pH8 using 1 N HC1 , then filter-sterilised .
- a stock solution of 10mM mevaionic acid lactone was prepared by dissolving the solid in dry ethanol , while farnesylpyrophosphate ( FPP) and geranylgeranylpyrophosphate (GGPP) , purchased from Sigma, were dried to remove solvent then resuspended in culture medium immediately before use.
- FPP farnesylpyrophosphate
- GGPP geranylgeranylpyrophosphate
- Methionine and mevalonolactone was from Amersham , Aylesbury , U K . All other chemicals were from Sigma Chemical Co, Poole, U K , unless stated otherwise.
- J774.2 cells were obtained from the European Collection of Animal Cell Cultures (Porton Down , UK) . Cultures were grown at 37° C in Dulbecco's Modified Eagle Medium (GIBCO, Paisley , UK) containing 10% heat inactivated foetal calf serum , 100 U/ml penicillin , 100 ⁇ g/ml streptomycin and 1 mM glutamine in 5% CCL atmosphere.
- Dulbecco's Modified Eagle Medium GIBCO, Paisley , UK
- Apoptosis in J774 macrophages was identified on the basis of characteristic changes in nuclear morphology i . e. condensation of chromarin and fragmentation of nuclei into apoptoric bodies , that distinguish apoptoric cells from cells undergoing necrotic cell death .
- J774 cells were seeded into 12 well plates ( Costar) at a density of 10 u per well . After 24h , the medium was replaced with fresh medium containing either 1 -1 OO ⁇ M mevastatin , 100 ⁇ M alendronate or 15 ⁇ M mevastatin , with or without 0.5 ⁇ M cycloheximide, 200 ⁇ M FPP, 200 ⁇ M GGPP or 200 ⁇ M mevaionic acid lactone . After 48h, both adherent and non-adherent cells were collected , fixed with 4% (v/v) formaldehyde than cytospun onto slides and visualised as described by Rogers et al.
- the adherent and non-adherent cells were collected and centrifuged at 1000g for 5 min .
- the cells were then lysed in 0.5ml RIPA buffer ( PBS , 0.1% (w/v) sodium dodecyl sulfate, 0.5% (w/v) sodium deoxycholate, 10 ⁇ g/ml phenylmethylsulfonyl fluoride) .
- the protein concentration of the lysates was determined using the BCA protein assay ( Pierce) .
- Equal quantities of protein ( usually 50 ⁇ g ) of each lysate were then electrophoresed on 12% polyacrylamide-SDS gels under reducing conditions . After electrophoresis , the gels were dried then visualised after exposed to a high sensitivity phosphoimaging screen ( BioRad ) for 3 days .
- Lysates for immunoprecipitation of Rab6 were precleared by using 1 ⁇ g of rabbit IgG and 20 ⁇ l protein A agarose slurry , followed by addition of 2 ⁇ g polyclonal rabbit a ⁇ ti-Rab6 (santa Cruz) for 2h , then 50 ⁇ l protein A-agarose and incubation overnight. Ras was immunoprecipitated by overnight incubation , at 4° , of 1 ml lysate with 30 ⁇ l pan-Ras antibody . Y13-259 conjugated to agarose beads (Oncogene Science) .
- Immunoprecipitates were washed 5 times with 1 ml RIPA buffer, then bound proteins were removed by boiling for 4 minutes in 30 ⁇ l Laemmli sample buffer. Finally, samples were electrophoresed on 12.5% polyacrylamide-SDS gels under reducing conditions and detected as described above.
- Mevastatin appeared to be more potent at inducing apoptosis than alendronate or risedronate, since concentrations of approximately 10 ⁇ M mevastatin , 30 ⁇ M alendronate or 3 ⁇ M risedronate caused 50% loss of total cell viability after 48h ( Fig .4) .
- Mevastatin-i ⁇ duced loss of cell viability could be prevented by co-incubating J774 cells with 15 ⁇ M mevastatin and 0.5 ⁇ M cycloheximide during the 48h culture period ( Fig .5) .
- Analysis of the proportion of morphologically apoptoric cells also demonstrated that cycloheximide prevented apoptosis (not shown) .
- Co- incubation with 200 ⁇ M FPP , GGPP or especially mevaionic acid lactone also prevented (at least partially) mevastatin-induced loss of cell viability and apoptosis ( Fig .6) .
- Bisphosphonates inhibit post-translational prenylation of proteins
- J774 cells metabolically-labelled with mevalonolactone for 24h contained radiolabelled proteins that could be separated by electrophoresis on 12% polyacrylamide gel into proteins of molecular weight 21-26kDa (mostly geranygeranylated GTP-binding proteins , but also farnesylated Ras proteins) , 60-70kDa (farnesylated lamin B and prelamin A) , 17kDa and 46kDa.
- a broad band at the migrating front of the gels (which did not stain with Coomassie blue and was not affected by prior treatment of cell
- Bisphosphonates inhibit farnesylation of Ras and geranylgeranylation of Rab6
- cycloheximide and actinomycin D prevent Ras transcription and hence prevent accumulation of non-prenylated , cytoplasmic Ras .
- Mevastatin is an inhibitor of HMG-CoA reductase and thus prevents synthesis of mevalonate.
- mevastatin-induced apoptosis could be prevented by addition of mevaionic acid lactone or the mevalonate-derived compounds FPP and GGPP.
- addition of either FPP or GGPP but not mevaionic acid lactone, partially prevented alendronate-induced apoptosis .
- alendronate appears to inhibit enzymes later in the mevalonate pathway than HMG-CoA reductase.
- Rho and Rac proteins play an important role in regulating cytoskeletal organisation and cell morphology, including membrane ruffling, and whose function is essential for bone resorption by osteoclasts .
- Loss of function of Rab proteins could affect intracellular membrane trafficking and vesicular transport from the Golgi , and could therefore prevent the insertion of proton pumps into the osteoclast ruffled border.
- Induction of osteoclast apoptosis could result from effects on lamins or on Ras signalling , as discussed above. It is most li kely that inhibition of bone resorption in vivo is actually a consequence of lack of prenylation of a multitude of osteoclast proteins .
- the extent to which prenylation is inhibited in osteoclasts may determine whether the cells simply lose the ability to function normally (i .e . fail to resorb bone) or whether this leads to induction of apoptoric cell death .
- bisphosphonates affect osteoclasts and other cells by interfering with cellular metabolism .
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Inhibiteurs soit de prényle transférase (farnésyle pyrophosphate synthase), soit d'isopentényle pyrophosphate isomérase, pouvant être mis en application dans différentes formes thérapeutiques et prophylactiques. L'invention concerne également l'utilisation de ces inhibiteurs dans le traitement de différentes maladies et de troubles du métabolisme osseux, ainsi que dans la recherche, l'isolement, la synthèse et l'évaluation de principes actifs ostéoactifs en tant qu'agents hypolipidémiques et anti-cancer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9610174.6A GB9610174D0 (en) | 1996-05-15 | 1996-05-15 | Prenyl transferase inhibitors |
GB9610174 | 1996-05-15 | ||
GB9708329 | 1997-04-25 | ||
GBGB9708329.9A GB9708329D0 (en) | 1997-04-25 | 1997-04-25 | Isopentenyl pyrophosphate iosmerase (IPI) and/or prenyl transferase inhibitors |
PCT/GB1997/001302 WO1997043437A2 (fr) | 1996-05-15 | 1997-05-12 | Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferase |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0952834A2 true EP0952834A2 (fr) | 1999-11-03 |
Family
ID=26309338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97921954A Withdrawn EP0952834A2 (fr) | 1996-05-15 | 1997-05-12 | Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferase |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0952834A2 (fr) |
AU (1) | AU2783397A (fr) |
WO (1) | WO1997043437A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6806076B1 (en) | 1998-04-14 | 2004-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing isoprenoid compounds by microorganisms and a method for screening compounds with antibiotic or weeding activity |
US7008645B2 (en) * | 1998-07-14 | 2006-03-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inhibiting restenosis using bisphosphonates |
IL125336A0 (en) * | 1998-07-14 | 1999-03-12 | Yissum Res Dev Co | Compositions for inhibition and treatment of restinosis |
US6984400B2 (en) * | 1998-07-14 | 2006-01-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of treating restenosis using bisphosphonate nanoparticles |
US6423519B1 (en) | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
PL349438A1 (en) * | 1998-12-23 | 2002-07-29 | Jomaa Pharmaka Gmbh | Use of bisphosphonates for the prevention and treatment of infectious processes |
EP1159447A4 (fr) * | 1999-03-05 | 2004-11-03 | Merck & Co Inc | Procedes d'identification de composes servant a inhiber la farnesyle diphosphate synthase |
CA2453817C (fr) * | 2001-07-20 | 2011-09-20 | Bioagency Ag | Composes organophosphores servant a activer des cellules t gamma/delta |
DE10242940A1 (de) * | 2002-09-16 | 2004-03-18 | Bayer Cropscience Ag | Verfahren zum Identifizieren von fungizid wirksamen Verbindungen |
US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
DE102005025191A1 (de) * | 2005-06-01 | 2006-12-14 | Bayer Cropscience Ag | Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Isopentenylpyrophosphat-Isomerasen |
KR101034299B1 (ko) * | 2008-12-02 | 2011-05-16 | 고려대학교 산학협력단 | Trpv3 활성 조절 약물 및 이의 활용 |
KR101034300B1 (ko) | 2008-12-02 | 2011-05-16 | 고려대학교 산학협력단 | Trpv3 활성 억제 약물 및 이의 활용 |
US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
CN112980809B (zh) * | 2021-03-17 | 2023-04-11 | 云南中烟工业有限责任公司 | 一种烟草法尼基焦磷酸合酶基因及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH675422A5 (fr) * | 1988-03-31 | 1990-09-28 | Symphar Sa | |
US5503973A (en) * | 1992-05-29 | 1996-04-02 | The Regents Of The University Of California | Method for inhibition of viral morphogenesis |
-
1997
- 1997-05-12 AU AU27833/97A patent/AU2783397A/en not_active Abandoned
- 1997-05-12 EP EP97921954A patent/EP0952834A2/fr not_active Withdrawn
- 1997-05-12 WO PCT/GB1997/001302 patent/WO1997043437A2/fr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9743437A3 * |
Also Published As
Publication number | Publication date |
---|---|
AU2783397A (en) | 1997-12-05 |
WO1997043437A3 (fr) | 1998-02-26 |
WO1997043437A2 (fr) | 1997-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997043437A2 (fr) | Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferase | |
Reszka et al. | Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation | |
Mönkkönen et al. | A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen‐containing bisphosphonates | |
Fleisch et al. | Bisphosphonates: mechanisms of action | |
Buhaescu et al. | Mevalonate pathway: a review of clinical and therapeutical implications | |
Roelofs et al. | Molecular mechanisms of action of bisphosphonates: current status | |
Wiemer et al. | Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase | |
EP1155121B1 (fr) | Compositions et procedes pour moduler le cholesterol serique | |
US20020035058A1 (en) | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors | |
Wiemer et al. | The intermediate enzymes of isoprenoid metabolism as anticancer targets | |
Holstein et al. | Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells | |
Thompson et al. | Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase | |
Zhou et al. | Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase | |
Finlay et al. | Selective inhibition of growth of tuberous sclerosis complex 2–null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity | |
AU651579B2 (en) | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
Peretz et al. | Cyclical pamidronate infusions in postmenopausal osteoporosis | |
Reilly et al. | Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis | |
EP0537007A1 (fr) | Utilisation d'inhibiteurs de farnésyl-protéine transferase pour la fabrication d'un médicament pour bloquer les transformations néoplastiques de cellules provoquées par des oncogènes ras | |
US8637274B2 (en) | Inhibitor for the formation of gamma-secretase complex | |
Merrell et al. | Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition | |
Cremers et al. | Clinical and translational pharmacology of bisphosphonates | |
WO2001075081A1 (fr) | Procedes d'identification de composes servant a inhiber la geranylgeranyl diphosphate synthase | |
EP1702626A1 (fr) | Inhibiteur de formation de complexe _g(g)-secretase | |
Scharnagl et al. | The effects of lifibrol (K12. 148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway | |
AU775239B2 (en) | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981215 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB IE IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 20010102 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20021203 |